Enanta Pharmaceuticals, Inc. ENTA
At closeNov 5, 2026, 4:01 PM EST
After hours · Nov 5, 4:01 PM ET
- YTD
- -36.08%
- 1 year
- -7.69%
- Market cap
- 293.58M
- Revenue (ttm)
- 71.96M
- Profit margin
- -160.27%
- EPS (ttm)
- -2.42
- Shares out
- 21.19M
- Forward P/E
- -1.32
- YTD return
- -36.08%
- 1-year return
- -7.69%
- Volume
- 317.35K
- Avg volume
- 252.25K
- Open
- 10.70
- Previous close
- 10.65
- Day's range
- 10.05 – 11.07
- 52-week range
- 10.08 – 16.85
- Beta
- 0.57
- Analysts
- Buy
- Price target
- 16.88 (+67.4%)
- Earnings date
- Feb 5, 2025
5D -0.94 (-8.53%)
Key statistics
- Enterprise value
- 187.00M
- PEG ratio
- 0.00
- Price / sales
- 1.88
- Price / book
- 0.91
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -4.90%
- Free cash flow
- -63.27M
- Total cash
- 230.08M
- Total debt
- 226.17M
- Return on equity
- -59.64%
- Short % of float
- 17.26%
- 50-day average
- 9.78
- 200-day average
- 12.44
Analyst view
Consensus: buy
- Target (low)
- 9.00
- Target (mean)
- 16.88
- Target (high)
- 27.00
- Strong buy2
- Buy2
- Hold3
- Sell0
- Strong sell1
Next earnings
Feb 5, 2025
Expected Feb 5, 2025. Consensus EPS estimate -1.27.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 5, 2025 | Dec 1, 2024 | -1.15 | — | — | — |
| Nov 25, 2024 | Sep 1, 2024 | -1.16 | -1.36 | -0.20 | -17.24% |
| Aug 5, 2024 | Jun 1, 2024 | -1.49 | -1.07 | +0.42 | +28.19% |
| May 6, 2024 | Mar 1, 2024 | -1.26 | -1.47 | -0.21 | -16.67% |
| Feb 7, 2024 | Dec 1, 2023 | -1.18 | -1.58 | -0.40 | -33.90% |
| Nov 20, 2023 | Sep 1, 2023 | -2.11 | -1.33 | +0.78 | +36.97% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 26, 2024 | Baird | main | Outperform | Outperform |
| Nov 26, 2024 | JMP Securities | reit | Market Outperform | Market Outperform |
| Oct 10, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 9, 2024 | JMP Securities | reit | Market Outperform | Market Outperform |
| Sep 27, 2024 | JMP Securities | reit | Market Outperform | Market Outperform |
| Aug 6, 2024 | JP Morgan | main | Underweight | Underweight |
About Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- enanta.com
News
Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences 
Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. 
Enanta Pharmaceuticals Doses First Patient In Its RESOLVE Phase 2b/3 Clinical Trial Of Zelicapavir In Adults At High Risk Of Severe Outcomes From RSV; Topline Data Expected In 2027 
Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV) 
Enanta Pharmaceuticals To Present Data For Zelicapavir, Oral, Once-Daily, N-Protein Inhibitor In Development For Treatment Of Respiratory Syncytial Virus At IDWeek 2026 
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026 
Comparing Enanta Pharmaceuticals (NASDAQ:ENTA) and Amphastar Pharmaceuticals (NASDAQ:AMPH) 
HC Wainwright & Co. Reiterates Buy on Enanta Pharma, Maintains $20 Price Target 
Bank of America Corp DE Reduces Stake in Enanta Pharmaceuticals, Inc. $ENTA 
Enanta Pharmaceuticals to Participate in September Investor Conferences
Your note
Sign in to keep a note on ENTA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GARDINER NATHANIEL S | Officer | Conversion of Exercise of derivative security | Feb 25, 2024 | 111,614 |
| KIEFFER TARA LYNN | Officer | Sale | Dec 5, 2024 | 29,305 |
| LULY JAY R | Chief Executive Officer | Sale | Dec 5, 2024 | 801,638 |
| LUU BRENDAN | Officer | Sale | Dec 5, 2024 | 36,047 |
| MELLETT PAUL J JR | Chief Financial Officer | Sale | Dec 5, 2024 | 91,710 |
| OR YAT SUN | Officer | Sale | Dec 5, 2024 | 369,109 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Farallon Capital Management LLC | 9.95% | 2,108,262 | 13.43M | Sep 29, 2024 |
| Vanguard Group Inc | 9.35% | 1,981,866 | 12.62M | Sep 29, 2024 |
| Blackrock Inc. | 8.97% | 1,900,323 | 12.11M | Sep 29, 2024 |
| Krensavage Asset Management, LLC | 7.07% | 1,498,074 | 9.54M | Sep 29, 2024 |
| Morgan Stanley | 5.20% | 1,102,852 | 7.03M | Sep 29, 2024 |
| Armistice Capital, LLC | 4.72% | 1,000,000 | 6.37M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.97% | 629,597 | 4.01M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.47% | 524,379 | 3.34M | Oct 30, 2024 |
| Vanguard Horizon Fund-Strategic Small-Cap Equity Fund | 1.42% | 300,762 | 1.92M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.33% | 281,611 | 1.79M | Sep 29, 2024 |
| Vanguard Variable Insurance Fund-Small Company Growth | 1.20% | 253,365 | 1.61M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.96% | 203,264 | 1.29M | Aug 30, 2024 |